Recent News

• 12.02.2025 - Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
• 11.24.2025 - Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
• 11.20.2025 - Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.06.2025 - Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
• 08.21.2025 - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investor Conference
• 08.21.2025 - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 08.14.2025 - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.14.2025 - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
• 06.30.2025 - Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

Recent Filings

• 11.21.2025 - EX-99.1 EX-99.1
• 11.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.11.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]